PubMed
Mechano growth factor E peptide (MGF-E), a muscle-specific splice variant of IGF-1
Yang et al., 2004
Healing & RecoveryResearch OnlyD
PEG-MGF
PEGylated Mechano Growth Factor
PEG-MGF (PEGylated mechano growth factor) is a polyethylene glycol-modified variant of the IGF-1 splice variant mechano growth factor (MGF), a local isoform of IGF-1 produced in muscles in response to mechanical loading or injury. PEGylation extends the half-life from minutes to approximately 5 days. Research demonstrates activation of muscle satellite cells and promotion of muscle hypertrophy and repair. Research only.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- D
- Experience
- 99
- Activity
- 80
Overall check-ins
Trackers & reports
Overview
About PEG-MGF
PEG-MGF (PEGylated mechano growth factor) is a polyethylene glycol-modified variant of the IGF-1 splice variant mechano growth factor (MGF), a local isoform of IGF-1 produced in muscles in response to mechanical loading or injury. PEGylation extends the half-life from minutes to approximately 5 days. Research demonstrates activation of muscle satellite cells and promotion of muscle hypertrophy and repair. Research only.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- PEGylated Mechano Growth Factor
- Self-reports
- 25
Community
What 25 users report
25 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
181
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
5
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 200–600 mcg
200–400
123
400–600
58
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 185 days · Based on 23 repeat reporters
Research
Cited research (1)
Source
Tools
Explore more
Explore
More ways to learn about PEG-MGF from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about PEG-MGF?
This page summarizes 25 anonymized self-reports from PeptIQ users who track PEG-MGF, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for PEG-MGF?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for PEG-MGF?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is PEG-MGF safe to use?
This wiki does not assess safety or recommend use. PEG-MGF is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of PEG-MGF?
Research, primarily in animal models, suggests PEG-MGF may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of PEG-MGF?
PEG-MGF is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified PEG-MGF as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of PEG-MGF?
The safety and effectiveness of PEG-MGF have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on PEG-MGF?
While there are over 200 published studies on PEG-MGF, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source